Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 6/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6220906 | 0.85 | HTR1A (0.62) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL6223321 | 0.84 | HTR1A (0.51) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL6743912 | 0.83 | HTR1A (0.53) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL6747869 | 0.82 | PARP1 (0.49) | HTR1AHTR7ABCC1DRD2HTR2A | |
| SCHEMBL27633026 | 0.79 | HTR1A (0.46) | HTR1AHTR7ABCC1CYP3A4DRD2 | |
| SCHEMBL6244932 | 0.78 | ABCC1 (0.51) | HTR1AHTR7ABCC1CYP3A4DRD2 | |
| SCHEMBL6220399 | 0.78 | HTR2A (0.51) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL6746368 | 0.77 | HTR1A (0.58) | HTR1AHTR7DRD2HTR2A | |
| Hydrochloric Acid SCHEMBL6750990 | 0.77 | HTR2A (0.50) | HTR1AHTR7DRD2HTR2A | |
| SCHEMBL6220537 | 0.75 | HTR2A (0.51) | HTR1AHTR7ABCC1CYP3A4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | ANDREANA TONJA LYNN (US) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138230-A1 | Heterocyclic substituted piperazines for the treatment of schizophrenia | CNR1, DRD2, CNR2 | HTR1A 17/4885HTR7 119/4885ABCC1 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.